Memo

Galantamine, the active ingredient in Memo, is an acetylcholinesterase inhibitor presented as an oral tablet for systemic use. It is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Memo as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards and regulatory oversight. The company ensures traceability, proper packaging, and compliance with EU and global pharmacopeial specifications for each shipment.

Galantamine is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

Alzheimer’s disease (mild to moderate): improves cognitive function and slows decline in daily activities. Memory loss in Alzheimer’s disease: helps preserve short‑term memory capabilities. Activities of daily living in Alzheimer’s disease: supports functional performance and independence.

Galantamine may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occurring after dosing. - Dizziness: sensation of light‑headedness, especially on standing. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate requiring medical attention. - Hepatotoxicity: elevated liver enzymes or liver injury. - Seizures: rare occurrence of convulsive episodes.

When prescribing galantamine, clinicians should consider several safety measures to minimize risk.

Dose titration: start with a low dose and increase gradually as tolerated. Renal impairment: adjust dose in patients with reduced kidney function. Hepatic impairment: monitor liver function and consider dose reduction. Cardiac conduction disorders: use with caution in patients with bradyarrhythmias. Concomitant anticholinergic drugs: avoid or monitor for reduced efficacy. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Galantamine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other acetylcholinesterase inhibitors: risk of cholinergic excess. - Potent anticholinergic agents: may diminish therapeutic effect. - Drugs that prolong the QT interval: increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise galantamine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower galantamine exposure. - Beta‑blockers: may enhance bradycardic effects of galantamine.